Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 11660.145 | 1.0077 | 1.0168 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 11660.145 | 0.9707 | 0.9361 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 11660.145 | 0.9878 | 0.9733 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11660.145 | 0.9949 | 0.9888 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 11660.145 | 1.0205 | 1.0447 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 11660.145 | 0.9918 | 0.9820 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 11660.145 | 0.9516 | 0.8947 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 11660.145 | 0.8524 | 0.6802 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 11660.145 | 0.9394 | 0.8681 | 0.9169 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12003.145 | 0.9908 | 0.9810 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12003.145 | 0.9442 | 0.8841 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12003.145 | 0.9932 | 0.9859 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12003.145 | 1.0156 | 1.0325 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12003.145 | 0.9947 | 0.9890 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12003.145 | 0.9945 | 0.9885 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12003.145 | 1.0232 | 1.0484 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12003.145 | 0.9869 | 0.9728 | 0.9611 | |
| ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12003.145 | 1.0298 | 1.0621 | 0.9611 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 11939.145 | 0.9819 | 0.9784 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 11939.145 | 0.9221 | 0.9059 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 11939.145 | 0.9655 | 0.9587 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11939.145 | 0.9737 | 0.9686 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 11939.145 | 0.9353 | 0.9220 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 11939.145 | 1.0569 | 1.0669 | 1.6830 | |
| ZR75B | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 11939.145 | 0.8800 | 0.8537 | 1.6830 |